Epclusa
FDA greenlights Gilead’s Epclusa in hepatitis C patients over six years old
March 20, 2020Medical Communications, Research and Development Epclusa, Gilead, pharma
Gilead’s Epclusa (sofosbuvir and velpatasvir) has been awarded new marketing approval from the FDA in the treatment of hepatitis C …
Gilead to release generic versions of hep C meds over a decade before patent expiry
September 28, 2018Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma
Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …
Provisional NICE recommendation for Gilead’s Hepatitis C treatment
September 28, 2016Research and Development, Sales and Marketing Epclusa, NICE, hepatitis C
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment …
Gilead receives EU approval for combo hepatitis C treatment
July 11, 2016Sales and Marketing Epclusa, Gilead, eu approval, sofosbuvir
Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for …
Gilead says US FDA approves Epclusa to treat hepatitis C
June 29, 2016Research and Development, Sales and Marketing Epclusa, Gilead, HCV, US FDA, drug approval, regulation
US drug firm Gilead Sciences (Nasdaq: GILD) said the US Food and Drug Administration has approved its Epclusa (sofosbuvir/velpatasvir), in …
Latest content
FibroFind appoints Lee Borthwick as CEO
